Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.35 |
| ▸ | GBA1 known ✓ | P04062 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL1845813 | 0.93 | TSHR (0.48) | TSHRPMP22GABRPGABRDGABRA1 | |
| Cadaverine Tartrate SCHEMBL29409197 | 0.82 | TSHR (0.47) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL80796 | 0.82 | TSHR (0.47) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL16527654 | 0.82 | TSHR (0.47) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL81366 | 0.82 | TSHR (0.47) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL29499522 | 0.82 | TSHR (0.47) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL1434088 | 0.78 | TSHR (0.44) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL11837339 | 0.78 | TSHR (0.44) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL11502416 | 0.78 | TSHR (0.44) | TSHRPMP22LMNACYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL845909 | 0.78 | TSHR (0.44) | TSHRPMP22LMNACYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154484-B2 | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof | ALLERGAN HOLDINGS FRANCE S.A.S. (FR) | 2021-10-26 | — | — | US | disclosed |
| EP-3184552-B1 | THREADS OF HYALURONIC ACID, METHODS OF MAKING THEREOF AND USES THEREOF | TAUTONA GROUP LP (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3243533-B1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | ALLERGAN HOLDINGS FRANCE S A S (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10463595-B2 | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof | ALLERGAN HOLDINGS FRANCE S.A.S. (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20180344610-A1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | TAUTONA GROUP LP | 2018-12-06 | — | — | US | disclosed |
| US-9861570-B2 | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof | ALLERGAN HOLDINGS FRANCE S.A.S. (FR) | 2018-01-09 | — | — | US | disclosed |
| EP-3243533-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | Allergan Holdings France S.A.S. (FR) | 2017-11-15 | — | — | EP | disclosed |
| EP-2324064-B1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | TAUTONA GROUP LP (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2979709-B1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND USE THEREOF | ALLERGAN HOLDINGS FRANCE S A S (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-3184552-A1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | Tautona Group LP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20130122068-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013055832-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2012054301-A1 | SOFT TISSUE AUGMENTATION THREADS AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054311-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF PREPARATION AND USE THEREOF | TAUTONA GROUP LP (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110263724-A1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | ALINE AESTHETICS, LLC | 2011-10-27 | — | — | US | disclosed |
| WO-2011109129-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109130-A1 | THREADS OF HYALURONIC ACID AND METHODS OF USE THEREOF | TAUTONA GROUP LP (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2324064-A1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | Tautona Group LP (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010028025-A1 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF | GURTNER GEOFFREY C (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010017526-A1 | PURINE NUCLEOTIDES ISOTOPICALLY LABELED IN THE PURINE BASE, METHODS OF MAKING THEREOF AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122068-A1 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF | CUTA, DSG1, COL14A1 | GABRA1 3598/4885GABRB1 4082/4885GABRG2 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.